Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiCOTTA study of clindamycin monotherapy versus rifampicin-based combination therapy for staphylococcal prosthetic joint infection
NL-OMON58956Phase 4Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in periprosthetic joint infection (PJI) and Staphylococcal periprosthetic joint infection (SPJI) comparing Clindamycin monotherapy with Rifampicin plus fluoroquinolone combination therapy (2 arms). Started May 2023; status: recruiting.
02
Drugs
clindamycinrifampicin
03
Conditions
periprosthetic joint infection (PJI)Staphylococcal periprosthetic joint infection (SPJI)
Beyond the preview
Go deeper on NL-OMON58956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58956.